Yes. For example, If all 10 patients display rapid and complete remission (particularly compared to existing public data on other interventions) you it would provide enough confidence to skip the cost of a Phase 2 (which is there to provide the numbers) and go straight to Ph3 (which gives you numbers but also compares to existing interventions).
- Forums
- ASX - By Stock
- SPL
- Astra Zeneca Quarterly
Astra Zeneca Quarterly, page-12
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SPL (ASX) to my watchlist
|
|||||
Last
9.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $39.64M |
Open | High | Low | Value | Volume |
9.7¢ | 9.7¢ | 9.5¢ | $19.64K | 204.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 69731 | 9.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.7¢ | 5390 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 69731 | 0.095 |
2 | 305855 | 0.094 |
2 | 320000 | 0.093 |
1 | 100000 | 0.092 |
4 | 49861 | 0.090 |
Price($) | Vol. | No. |
---|---|---|
0.097 | 5390 | 1 |
0.098 | 200000 | 1 |
0.100 | 106000 | 3 |
0.105 | 148467 | 3 |
0.110 | 183058 | 5 |
Last trade - 16.10pm 09/09/2024 (20 minute delay) ? |
Featured News
SPL (ASX) Chart |